The product covered by this technical introduction is Testosterone Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. The substance is 17β-hydroxyandrost-4-en-3-one, CAS 58-22-0, molecular formula C19H28O2, relative molecular mass 288.42 g/mol. In manufacturing documentation it is identified as VetGrade Testosterone Base T-100; the numeric suffix 100 denotes release alignment with the pharmacopeial assay target and does not represent a finished veterinary product strength. The API is supplied as a non-sterile white to almost white crystalline powder in either a micronized or a non-micronized crystalline grade. Pharmacopeial identity is established against the USP Testosterone monograph and the EP Testosterone monograph. The material is intended strictly for incorporation into finished veterinary medicinal products under appropriate manufacturing authorization. It is not sterile, not pyrogen-free by default, and not intended for direct administration or for food-producing species unless the receiving regulatory file explicitly provides such allowance.

Because no separate veterinary monograph for testosterone base exists in most jurisdictions, release and stability testing follow the same public monograph specifications as the active substance, with additional veterinary documentation for residual solvents, elemental impurities, and stability under VICH GL18, GL3, and GL4 as applicable. The material is practically insoluble in water and freely soluble in ethanol and methylene chloride according to the EP solubility statements. That solubility profile directs formulation toward suspension, granulation, premix, or non-aqueous liquid approaches rather than simple aqueous dissolution. The unesterified base differs from testosterone esters in that it has no hydrolytically cleaved side chain at the 17β position; this is the principal structural distinction controlling oil solubility and release duration.

Why does the unesterified base require different formulation routes than testosterone esters?

The unesterified base is active without esterase-mediated hydrolysis, but its low water solubility and limited solubility in fixed oils restrict its use in high-concentration oily injections. Testosterone cypionate and testosterone enanthate are synthesized by esterification at the 17β-hydroxyl group, yielding relative molecular masses of 412.61 g/mol and 400.59 g/mol, respectively. Those esters partition into sesame oil, castor oil, or synthetic triglycerides sufficiently to achieve high depot concentrations in some injectable veterinary formulations, whereas the unesterified base is more commonly processed into micronized aqueous suspensions or solid oral dosage forms. The absence of an ester side chain removes the requirement for hydrolytic release but also shortens absorption from aqueous suspensions and lowers lipophilicity. This difference in release pathways is the reason a single API particle-size grade cannot simultaneously optimize all dosage forms.

When milled to a laser-diffraction Dv90 below 15 µm, the API can be formulated into aqueous suspensions that pass through 21-gauge or 22-gauge hypodermic needles. Non-micronized crystalline material with Dv90 up to 75 µm is typically reserved for granulation, capsule filling, and premix operations where blend flow and segregation control are more important than syringeability. The micronized grade may show high interparticle cohesion and poor powder flow, requiring glidant addition at the site of use. The non-micronized grade generally flows more readily but requires further particle-size reduction if an aqueous injectable suspension is the intended finished form.

Monograph-aligned specifications and residue control

Release under the USP and EP frameworks requires confirmation of identity, purity, crystalline character, residual solvents, and elemental impurities. The principal release characteristics are summarized in the following table. Values represent current pharmacopeial limits or, where indicated, the manufacturer’s specification for particle-size control.

At incoming quality control, particle-size distribution is often the first indicator of batch-to-batch variability because milling conditions affect both the Dv90 and the specific surface area. The dry powder is cohesive; on production-scale blenders, blend uniformity is governed by the finished-product test for content uniformity under USP <905>. If the Dv90 shifts above 20 µm, in-process homogenization or high-shear dispersion for injectable suspensions can become rate-limiting. Re-milling of the API at the compounding site is not recommended because additional mechanical energy can increase amorphous content, alter electrostatic charge, and reduce blend consistency.

When micronization for injectable suspensions conflicts with dry powder flow in tablet manufacture

This conflict is most visible in veterinary tablets and capsules that use the same API source but require two different particle-size ranges. Direct-compression formulations based on the micronized grade exhibit higher interparticle cohesion, lower bulk density, and higher Carr index values than formulations using the crystalline grade. Under powder-flow classification in USP <1174>, a powder with a Carr index above 38 is considered very poor-flowing; micronized testosterone base can approach this range unless a glidant such as colloidal silicon dioxide is incorporated at 0.5% to 1.0% w/w. The same glidant can interfere with aqueous suspension wetting if carried into an injectable formulation, so separate supply chains and equipment contact parts are required for dry-dosage and suspension processing.

For tablets, low-dose uniformity is controlled by USP <905>. If the micronized API is used, wet granulation may be required because direct compression of a cohesive low-dose powder is difficult on rotary tablet presses. Granulation with purified water and a binder such as povidone in a high-shear mixer improves flow and content uniformity but raises residual moisture; drying to a loss-on-drying not more than 2.0% w/w is therefore a critical endpoint before compression. Similar logic applies to hard gelatin capsules, where granulation reduces segregation during encapsulation. Premix and granules for oral dosing are best manufactured by geometric dilution in a V-blender or bin blender, followed by sieving; the final blend is tested for assay and blend uniformity before filling or tableting.

What terminal-sterilization limits apply to aqueous suspensions of the base?

For injectable dosage forms, the API is suspended rather than dissolved. Aqueous vehicles containing preservatives, wetting agents, and tonicity adjusters are used. High-pressure homogenization is sometimes required to reduce particle aggregates and ensure that the suspension passes through the intended needle gauge. Because suspensions cannot be sterile-filtered, downstream processing must use either aseptic manufacture or terminal steam sterilization. Terminal steam sterilization at 121°C for 15 minutes can be suitable for heat-stable formulations, but it may accelerate particle aggregation and vehicle viscosity changes. Testosterone base has a melting range of 153°C to 157°C, so steam sterilization remains below the melt; nevertheless, aseptic processing of the sterile suspension is often selected when terminal sterilization validation is not available. The non-sterile API must carry a bioburden specification. Typical supplier release targets are total aerobic microbial count not more than 100 CFU/g and total combined yeasts and moulds not more than 10 CFU/g, with enumeration according to USP <61> and specified-organism testing according to USP <62>. Published data for this specific formulation configuration are limited; each finished suspension must be validated for its own terminal-sterilization or aseptic-processing boundary.

For oral solutions and liquid-filled capsules, the base is dissolved in lipophilic or water-miscible solvent systems after confirming solubility in the selected vehicle. The crystalline grade is generally preferred for dissolution testing because micronized material can alter apparent dissolution kinetics. Solutions for oral dosing are non-sterile but must be protected from microbial growth through the finished formulation preservative system or by single-dose packaging. The API itself should not be stored in high-humidity environments above 60% RH because surface moisture adsorption can promote agglomeration and reduce chemical stability.

Esterification changes the handling and release profile of the same active nucleus

The comparative table below outlines the structural and dosage-form differences between the veterinary base and the common testosterone esters. These differences define the selection logic for finished veterinary medicines.

The base is therefore selected for aqueous suspensions and immediate oral forms, while the esterified compounds are selected for depot injections. In veterinary practice, the base is frequently used with an ester-free label to avoid variability arising from species-specific esterase activity. However, esterase activity differs across dogs, horses, and cattle, and extrapolation of human pharmacokinetic data to veterinary target species is not reliable. Published data for many specific veterinary target-species configurations are limited, so the release profile must be confirmed in the target species rather than inferred from human depot kinetics.

Regional residue controls restrict food-animal applications unless explicitly approved

In jurisdictions following FDA 21 CFR 500 or EU veterinary medicinal product frameworks, the use of testosterone in food-producing species may be restricted or prohibited, and withdrawal periods are not generally established for unapproved hormonal use. The API is non-sterile and must not be used in final dosage forms without valid manufacturing authorization and veterinary prescription. Regional import permits often require a veterinary drug master file, residual solvent data under VICH GL18, and stability data under VICH GL3 and GL4 for storage conditions. Packaging is typically double low-density polyethylene bags inside a high-density polyethylene drum, with nitrogen overlay. Exposure to strong oxidizers should be avoided because the 17β-hydroxyl and 3-keto groups are susceptible to oxidative degradation. The dry substance is stable when protected from light and stored in a tight container at controlled room temperature. Sterility, pyrogen-free status, and injection-ready properties are not inherent attributes of this API and must be generated by downstream processing under the responsibility of the finished-product manufacturer.